Sign in or create an account to add this stock to your watchlist.
About TransEnterix (NYSEAMERICAN:TRXC)
TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.
Industry, Sector and Symbol
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:TRXC
CUSIPN/A
Phone+1-919-7658400
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-21,045.36%
Return on Equity-137.69%
Return on Assets-83.60%
Miscellaneous
EmployeesN/A
Outstanding Shares201,970,000
TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions
What is TransEnterix's stock symbol?
TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."
How were TransEnterix's earnings last quarter?
TransEnterix, Inc. (NYSEAMERICAN:TRXC) issued its quarterly earnings data on Tuesday, May, 8th. The medical instruments supplier reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The medical instruments supplier had revenue of $4.77 million for the quarter, compared to analyst estimates of $3.81 million. TransEnterix had a negative net margin of 21,045.36% and a negative return on equity of 137.69%. View TransEnterix's Earnings History.
What price target have analysts set for TRXC?
3 brokers have issued 1 year target prices for TransEnterix's stock. Their predictions range from $4.00 to $5.00. On average, they anticipate TransEnterix's share price to reach $4.50 in the next year. View Analyst Ratings for TransEnterix.
Are investors shorting TransEnterix?
TransEnterix saw a increase in short interest in the month of April. As of April 30th, there was short interest totalling 23,293,649 shares, an increase of 2.4% from the April 13th total of 22,736,694 shares. Based on an average daily trading volume, of 1,695,351 shares, the days-to-cover ratio is presently 13.7 days. Currently, 15.5% of the company's shares are short sold.
Who are some of TransEnterix's key competitors?
Some companies that are related to TransEnterix include Advanced Medical Solutions (AMS), CRH Medical (CRHM), Tristel (TSTL), TSO3. (TOS), Clover (CLV), Bovie Medical (BVX), Infusystem (INFU), Retractable Technologies (RVP), Milestone Scientific (MLSS), Akers Biosciences (AKR), Daxor (DXR), Omega Diagnostics Group (ODX), Relevium Technologies (RLV), Vigil Health Solutions (VGL) and Iris Biotechnologies (IRSB).
Who are TransEnterix's key executives?
TransEnterix's management team includes the folowing people:
- Mr. Todd M. Pope, CEO, Pres & Director (Age 53)
- Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)
- Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)
- Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)
- Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52)
Has TransEnterix been receiving favorable news coverage?
Headlines about TRXC stock have trended somewhat positive on Wednesday, according to Accern. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. TransEnterix earned a news sentiment score of 0.15 on Accern's scale. They also gave news articles about the medical instruments supplier an impact score of 46.02 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are TransEnterix's major shareholders?
TransEnterix's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (3.60%), Millennium Management LLC (0.94%), Royal Bank of Canada (0.58%), UBS Group AG (0.45%), Tibra Equities Europe Ltd (0.17%) and Element Capital Management LLC (0.10%). Company insiders that own TransEnterix stock include Andrea Biffi, Anthony C J Fernando, Joseph P Slattery, Richard C Pfenniger Jr, SPA Sofar, Todd Pope and Willam N Kelley. View Institutional Ownership Trends for TransEnterix.
Which major investors are buying TransEnterix stock?
TRXC stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, UBS Group AG, Tibra Equities Europe Ltd, Element Capital Management LLC, JPMorgan Chase & Co., Royal Bank of Canada and Barclays PLC. Company insiders that have bought TransEnterix stock in the last two years include Andrea Biffi, Anthony C J Fernando, Richard C Pfenniger Jr, SPA Sofar and Willam N Kelley. View Insider Buying and Selling for TransEnterix.
How do I buy shares of TransEnterix?
Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TransEnterix's stock price today?
One share of TRXC stock can currently be purchased for approximately $3.07.
How big of a company is TransEnterix?
TransEnterix has a market capitalization of $354.65 million.
How can I contact TransEnterix?
TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.
MarketBeat Community Rating for TransEnterix (TRXC)
MarketBeat's community ratings are surveys of what our community members think about TransEnterix and other stocks. Vote "Outperform" if you believe TRXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
TransEnterix (NYSEAMERICAN:TRXC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for TransEnterix in the last 12 months. Their average twelve-month price target is $4.50, suggesting that the stock has a possible upside of 46.58%. The high price target for TRXC is $5.00 and the low price target for TRXC is $4.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 2.50 | 2.50 | 2.67 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.50 | $3.2333 | $3.2333 | $3.2333 |
| Price Target Upside: | 46.58% upside | 39.97% upside | 39.97% upside | 12.66% upside |
TransEnterix (NYSEAMERICAN:TRXC) Consensus Price Target History
TransEnterix (NYSEAMERICAN:TRXC) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
TransEnterix (NYSEAMERICAN:TRXC) Earnings History and Estimates Chart
TransEnterix (NYSEAMERICAN TRXC) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/8/2018 | Q1 2018 | ($0.07) | ($0.06) | $3.81 million | $4.77 million | View | N/A |  |
| 3/6/2018 | Q4 2017 | ($0.06) | ($0.40) | $3.46 million | $3.40 million | View | N/A | |
| 11/9/2017 | Q3 2017 | ($0.09) | ($0.09) | $0.01 million | $0.18 million | View | N/A | |
| 8/2/2017 | Q2 2017 | ($0.11) | ($0.11) | $0.87 million | $1.58 million | View | N/A | |
| 5/10/2017 | Q1 2017 | ($0.12) | ($0.13) | $1.72 million | $1.95 million | View | N/A | |
| 3/6/2017 | Q4 2016 | ($0.11) | ($0.12) | $0.91 million | $0.05 million | View | Listen | |
| 11/9/2016 | Q316 | ($0.10) | ($0.11) | $1.80 million | $1.50 million | View | Listen | |
| 8/5/2016 | Q2 2016 | ($0.13) | ($0.11) | | | View | N/A | |
| 5/10/2016 | Q116 | ($0.13) | ($0.12) | | | View | Listen | |
| 3/3/2016 | Q415 | ($0.12) | ($0.13) | | | View | N/A | |
| 11/9/2015 | Q3 2015 | ($0.11) | ($0.11) | | | View | N/A | |
| 8/6/2015 | Q215 | ($0.15) | ($0.14) | | | View | N/A | |
| 5/6/2015 | Q115 | ($0.17) | ($0.16) | $0.03 million | | View | N/A | |
| 2/24/2015 | Q414 | ($0.18) | ($0.13) | $50.00 million | $0.13 million | View | N/A | |
| 11/6/2014 | Q3 | ($0.18) | ($0.18) | $0.10 million | $0.06 million | View | N/A | |
| 8/6/2014 | Q2 2014 | ($0.13) | ($0.18) | $0.09 million | $0.11 million | View | N/A | |
| 5/7/2014 | | ($0.14) | ($0.15) | $0.20 million | $0.09 million | View | N/A | |
| 3/5/2014 | Q4 2013 | | ($0.20) | | $0.22 million | View | N/A | |
| 11/12/2013 | Q3 2013 | | ($0.60) | | $0.36 million | View | N/A | |
| 8/14/2013 | Q2 2013 | | ($0.10) | | $0.01 million | View | N/A | |
| 5/15/2013 | Q1 2013 | | ($0.05) | | $0.01 million | View | N/A | |
| 4/1/2013 | Q4 2012 | | ($0.15) | | | View | N/A | |
| 11/14/2012 | Q3 2012 | | ($0.15) | | | View | N/A | |
| 8/14/2012 | Q2 2012 | | ($0.20) | | | View | N/A | |
| 5/15/2012 | Q1 2012 | | ($0.28) | | | View | N/A | |
| 3/30/2012 | Q4 2011 | | ($0.28) | | | View | N/A | |
| 11/14/2011 | Q3 2011 | | ($0.27) | | | View | N/A | |
| 8/12/2011 | Q2 2011 | | ($0.24) | | | View | N/A | |
| 5/16/2011 | Q1 2011 | | ($0.24) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
TransEnterix (NYSEAMERICAN:TRXC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
TransEnterix (NYSEAMERICAN TRXC) Insider Trading and Institutional Ownership History
TransEnterix (NYSEAMERICAN TRXC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/16/2017 | Joseph P Slattery | CFO | Sell | 529,609 | $2.80 | $1,482,905.20 | 440,974 | |
| 11/14/2017 | Joseph P Slattery | CFO | Sell | 333,000 | $2.93 | $975,690.00 | 440,974 | |
| 10/18/2017 | Todd Pope | Insider | Sell | 600,000 | $3.68 | $2,208,000.00 | 462,644 | |
| 8/8/2017 | Willam N Kelley | Director | Buy | 30,000 | $0.71 | $21,300.00 | | |
| 5/16/2017 | Richard C Pfenniger Jr | Director | Buy | 100,000 | $0.54 | $54,000.00 | 148,000 | |
| 1/4/2017 | S.P.A Sofar | Major Shareholder | Buy | 3,722,685 | $1.40 | $5,211,759.00 | 19,266,098 | |
| 8/22/2016 | Andrea Biffi | Director | Buy | 40,000 | $1.40 | $56,000.00 | 90,000 | |
| 6/14/2016 | Anthony C J Fernando | CTO | Buy | 27,000 | $1.46 | $39,420.00 | 27,000 | |
| 5/13/2016 | Joseph P Slattery | CFO | Buy | 50,000 | $1.92 | $96,000.00 | 172,387 | |
| 11/16/2015 | Andrea Biffi | Director | Buy | 25,000 | $2.81 | $70,250.00 | 50,000 | |
| 11/13/2015 | Willam N Kelley | Director | Buy | 20,000 | $2.80 | $56,000.00 | | |
| 11/12/2015 | Joseph P Slattery | CFO | Buy | 15,000 | $2.77 | $41,550.00 | 135,087 | |
| 10/2/2014 | Joseph P Slattery | CFO | Sell | 33,000 | $4.19 | $138,270.00 | | |
| 9/8/2014 | Richard Mueller | COO | Sell | 3,000 | $3.60 | $10,800.00 | | |
| 9/8/2014 | Todd Pope | CEO | Sell | 50,000 | $3.70 | $185,000.00 | | |
| 4/21/2014 | Aisling Capital Iii Lp | Major Shareholder | Buy | 1,037,767 | $4.00 | $4,151,068.00 | | |
| 4/21/2014 | William N Starling Jr | Director | Buy | 221,450 | $4.00 | $885,800.00 | | |
(Data available from 1/1/2013 forward)
TransEnterix (NYSEAMERICAN TRXC) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Why TransEnterix, Inc. Stock Bolted Higher Today
www.fool.com - May 21 at 6:12 PM |
 | 5 Must-Read Quotes From TransEnterix's Big First Quarter
finance.yahoo.com - May 17 at 7:08 PM |
| Options Traders Expect Huge Moves in TransEnterix (TRXC) Stock
finance.yahoo.com - May 16 at 5:54 PM |
 | TransEnterix (TRXC) Soars: Stock Adds 14.2% in Session
www.zacks.com - May 15 at 8:15 AM |
| Edited Transcript of TRXC earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 11 at 6:09 PM |
 | BTIG Upgrades TransEnterix (TRXC) to Buy
www.streetinsider.com - May 10 at 8:12 AM |
 | Zacks Investment Research Upgrades SafeStitch Medical (TRXC) to "Hold"
www.americanbankingnews.com - May 9 at 6:59 PM |
| Here's Why TransEnterix Is Soaring Today
finance.yahoo.com - May 9 at 5:45 PM |
| SafeStitch Medical Inc. (TRXC) Short Interest Update
www.americanbankingnews.com - May 9 at 5:25 PM |
| SafeStitch Medical (TRXC) Upgraded by BTIG Research to "Buy"
www.americanbankingnews.com - May 9 at 1:29 PM |
| SafeStitch Medical (TRXC) Posts Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 9 at 12:59 PM |
| TransEnterix: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 8:08 AM |
| TransEnterix, Inc. Reports Operating and Financial Results for the First Quarter 2018
finance.yahoo.com - May 8 at 5:50 PM |
| SafeStitch Medical (TRXC) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - May 2 at 8:47 PM |
| Edited Transcript of TRXC earnings conference call or presentation 6-Mar-17 9:30pm GMT
finance.yahoo.com - April 25 at 5:37 PM |
| TransEnterix Inc (NYSEMKT:TRXC): Does The -20.68% Earnings Drop Reflect A Longer Term Trend?
finance.yahoo.com - April 25 at 5:37 PM |
| SafeStitch Medical Inc. (TRXC) Short Interest Up 1.0% in April
www.americanbankingnews.com - April 24 at 6:58 PM |
| TransEnterix Schedules First Quarter 2018 Financial and Operating Results Conference Call for May 8, 2018
finance.yahoo.com - April 24 at 8:11 AM |
| SafeStitch Medical (TRXC) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 18 at 2:58 PM |
| Is There Now An Opportunity In TransEnterix Inc (NYSEMKT:TRXC)?
finance.yahoo.com - April 14 at 8:12 AM |
| SafeStitch Medical Inc. (TRXC) Short Interest Up 3.4% in March
www.americanbankingnews.com - April 10 at 6:56 PM |
| Why TransEnterix Fell 10.5% in March
finance.yahoo.com - April 5 at 5:25 PM |
| Transenterix (TRXC) PT Raised to $4.00
www.americanbankingnews.com - April 3 at 9:54 PM |
| Transenterix Inc (TRXC) Sees Large Increase in Short Interest
www.americanbankingnews.com - March 26 at 6:32 PM |
| Transenterix Inc (TRXC) Short Interest Up 14.9% in February
www.americanbankingnews.com - March 9 at 6:02 PM |
| Transenterix (TRXC) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 8 at 7:03 PM |
| TransEnterix Management Talks Growth, Product Enhancements, Financing, and More
finance.yahoo.com - March 8 at 6:56 PM |
 | Transenterix (NYSE:TRXC) - TransEnterix Q4 Earnings Preview ... - Benzinga
www.benzinga.com - March 7 at 8:09 AM |
| TransEnterix Q4 Earnings Preview
finance.yahoo.com - March 6 at 5:47 PM |
| TransEnterix, Inc. to Host Earnings Call
finance.yahoo.com - March 6 at 5:47 PM |
| TransEnterix, Inc. Reports Operating Results for the Fourth Quarter and Full Year 2017
finance.yahoo.com - March 6 at 5:47 PM |
| Transenterix Inc (TRXC) Reports Results for 2017 4Q and Full Year
finance.yahoo.com - March 6 at 5:47 PM |
| EAM Investors LLC Invests $1.33 Million in Transenterix Inc (TRXC)
www.americanbankingnews.com - March 3 at 5:40 AM |
| Transenterix Inc (TRXC) Short Interest Update
www.americanbankingnews.com - February 27 at 5:40 PM |
| What's Pushing Up TransEnterix Inc. Stock Today? - Motley Fool
www.fool.com - February 27 at 8:09 AM |
 | What's Pushing Up TransEnterix Inc. Stock Today?
www.msn.com - February 26 at 5:51 PM |
| What's Pushing Up TransEnterix Inc. Stock Today?
finance.yahoo.com - February 26 at 5:51 PM |
| Why TransEnterix Is Rising Today
finance.yahoo.com - February 21 at 5:33 PM |
| New Research: Key Drivers of Growth for Stag Industrial, Heartland Express, Antero Midstream Partners LP, TransEnterix, A-Mark Precious Metals, and Franklin Street Properties — Factors of Influence, Major Initiatives and Sustained Production
finance.yahoo.com - February 20 at 8:10 AM |
| TransEnterix Announces FDA 510(k) Submission for Senhance Indication Expansion to More than Double Addressable Market in the U.S. and Provides Commercial Update
finance.yahoo.com - February 14 at 8:49 AM |
| TransEnterix to Present at the RBC Capital Markets 2018 Global Healthcare Conference
finance.yahoo.com - February 7 at 8:31 AM |
| TransEnterix to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - January 31 at 8:43 AM |
 | This Morning's Technical Outlook on Medical Supplies Stocks -- TransEnterix, Akers Biosciences, Antares Pharma, and Microbot Medical
www.prnewswire.com - January 30 at 8:32 AM |
| Short Interest in Transenterix Inc (TRXC) Increases By 6.4%
www.americanbankingnews.com - January 24 at 5:40 PM |
| Transenterix (TRXC) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - January 23 at 6:08 PM |
| Edited Transcript of TRXC earnings conference call or presentation 10-May-17 8:30pm GMT
finance.yahoo.com - January 18 at 3:33 PM |
| Transenterix Inc (TRXC) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 13 at 4:01 AM |
| Transenterix (TRXC) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - January 11 at 3:32 PM |
| Here's Why TransEnterix Rallied 47% in 2017
finance.yahoo.com - January 9 at 4:11 PM |
| TransEnterix (TRXC) Announces 2017 Year-End Corporate Update - StreetInsider.com
www.streetinsider.com - January 8 at 3:36 PM |
TransEnterix (NYSEAMERICAN:TRXC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
TransEnterix (NYSEAMERICAN:TRXC) Income Statement, Balance Sheet and Cash Flow Statement
TransEnterix (NYSEAMERICAN TRXC) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
